Ghassan Abou-Alfa

Ghassan Abou-Alfa at Memorial Sloan Kettering led the ClarIDHy phase III trial that established ivosidenib as the first IDH1 inhibitor approved for advanced IDH1-mutant cholangiocarcinoma, representing a major precision oncology milestone. His broader research spans hepatocellular carcinoma and biliary tract cancers, with contributions to sorafenib, regorafenib, and immunotherapy trials in HCC. He has been a leading figure in international hepatobiliary cancer trials through NCCN, ASCO, and ESMO guideline activities. His translational work on IDH mutations in CCA has defined the therapeutic rationale for IDH inhibition.